Biotech company Alumis has raised $250 million for pivotal tests on its lead drug candidate for treating plaque psoriasis. The drug targets the enzyme TYK2 involved in inflammation pathways. Alumis aims to show that its drug, ESK-001, can achieve complete inhibition of TYK2 without causing safety issues, unlike competitors’ drugs that have shown limitations in clinical testing. The company also has a second program, A-005, which has the potential to address neuroinflammatory diseases. Alumis, incubated by Foresite Labs, plans to begin Phase 3 tests for ESK-001 later this year and expects to report results from its studies in 2026.
Source link
Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials
